Our strategy

Inspired by our Values and what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for patients and society.

Our strategy is straightforward.

We are science and innovation-led and have a diversified portfolio of medicines across primary, specialty care and rare diseases.

We are focused on leading in the therapy areas where we believe we can make the most meaningful difference to patients: Oncology; BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism and Respiratory & Immunology); and Rare Disease.

We have global strength with balanced presence across regions.

We are committed to operating in a way that recognises the interconnection between business growth, the needs of society and the limitations of our planet.

We have three priorities designed to deliver our strategy.

  • Accelerate innovative science

    Advancing high-potential late-stage pipeline projects, pursuing the next wave of disruptive biology and accelerating efforts in AI, data science and digital technology

  • Deliver growth and therapy area leadership

    Driving growth, impacting and improving the whole patient journey and collaborating with the funders of healthcare

  • Be a great place to work

    Our commitment to society and our people